BHC
Bausch Health Companies Inc
$
6.030
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.150
Open
6.000
VWAP
6.06
Vol
1.31M
Mkt Cap
2.23B
Low
5.9506
Amount
7.91M
EV/EBITDA(TTM)
6.98
Total Shares
366.80M
EV
22.89B
EV/OCF(TTM)
15.20
P/S(TTM)
0.22
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
2.61B
+3.01%
0.967
+6.77%
2.42B
+7%
0.767
+26.33%
2.72B
+6.14%
1.252
+7.93%
Estimates Revision
The market is revising No Change the revenue expectations for Bausch Health Companies Inc. (BHC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -19.49%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.01%
In Past 3 Month
Stock Price
Go Down
-19.49%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast BHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHC is 8.33 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
4 Hold
0 Sell
Hold
Current: 6.030
Low
7.00
Averages
8.33
High
10.00
Current: 6.030
Low
7.00
Averages
8.33
High
10.00
BofA
Craig Bijou
Underperform
maintain
$11 -> $13
2025-08-04
Reason
BofA
Craig Bijou
Price Target
$11 -> $13
2025-08-04
maintain
Underperform
Reason
BofA analyst Craig Bijou raised the firm's price target on Bausch + Lomb (BLCO) to $13 from $11 and keeps an Underperform rating on the shares. Shares were up 13% in July before results as investors had grown more optimistic that a separation from Bausch Health (BHC) was getting closer, but B+L shares were down 8% over Wednesday to Friday of last week despite a Q2 beat and raise, the analyst noted. The firm still believes that "investor interest will be limited until there is more visibility on the separation," the analyst added in a post-earnings note.
Jefferies
David Steinberg
Strong Buy
to
Hold
Downgrades
$12 → $8
2025-02-06
Reason
Jefferies
David Steinberg
Price Target
$12 → $8
2025-02-06
Downgrades
Strong Buy
to
Hold
Reason
Jefferies downgraded Bausch Health to Hold from Buy.
RBC Capital
Douglas Miehm
Hold
Maintains
$11 → $10
2025-01-30
Reason
RBC Capital
Douglas Miehm
Price Target
$11 → $10
2025-01-30
Maintains
Hold
Reason
RBC Capital lowered the firm's price target on Bausch Health (BHC) to $10 from $11 and keeps a Sector Perform rating on the shares ahead of its Q4 results. The firm is adjusting its model as it reduces the BLCO - Bausch + Lomb - sale scenario, weighting to 60% from 75% given the recent news of Blackstone (BX) likely dropping out of consortium with TPG to take out BLCO, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bausch Health Companies Inc (BHC.N) is 1.48, compared to its 5-year average forward P/E of 3.32. For a more detailed relative valuation and DCF analysis to assess Bausch Health Companies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
3.32
Current PE
1.48
Overvalued PE
5.58
Undervalued PE
1.06
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
8.06
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.17
Undervalued EV/EBITDA
6.95
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.54
Current PS
0.00
Overvalued PS
0.92
Undervalued PS
0.15
Financials
Annual
Quarterly
FY2025Q3
YoY :
+6.81%
2.68B
Total Revenue
FY2025Q3
YoY :
+35.54%
717.00M
Operating Profit
FY2025Q3
YoY :
-296.74%
181.00M
Net Income after Tax
FY2025Q3
YoY :
-308.70%
0.48
EPS - Diluted
FY2025Q3
YoY :
-5.99%
314.00M
Free Cash Flow
FY2025Q3
YoY :
+2.02%
62.59
Gross Profit Margin - %
FY2025Q3
YoY :
+1.50%
10.81
FCF Margin - %
FY2025Q3
YoY :
-283.92%
6.75
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
97.7K
USD
1
3-6
Months
121.9K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
8
369.6M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
2.7M
Volume
3
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
4.2M
Volume
Months
0-12
2
3.5M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
97.7K
USD
1
3-6
Months
121.9K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
8
369.6M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BHC News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
08:29:56
Bausch Health's OraPharma Launches Operations in Canada and Puerto Rico
2025-10-29 (ET)
2025-10-29
16:58:28
Bausch Health projects FY25 revenue between $10.05B and $10.25B, with consensus at $10.12B
2025-10-29
16:56:19
Bausch Health Announces Q3 Revenue of $2.68 Billion, Exceeding Consensus of $2.63 Billion
Sign Up For More Events
Sign Up For More Events
News
4.0
11-19NASDAQ.COMBausch (BHC) Receives Upgrade to Buy: Reasons Explained
5.0
11-17BenzingaHedge Fund Tycoon Carl Icahn's Q3: The Activist Takes a Defensive Stance, Sells Off a Troubling Investment, and Increases Stake in EchoStar
3.0
11-15Yahoo FinanceBausch Health (NYSE:BHC) Valuation Revision Following OraPharma's Market Expansion
Sign Up For More News
People Also Watch
PRVA
Privia Health Group Inc
23.740
USD
+5.28%
YELP
Yelp Inc
28.800
USD
-0.17%
PSMT
PriceSmart Inc
118.580
USD
+0.91%
FFBC
First Financial Bancorp
24.440
USD
+3.21%
STNG
Scorpio Tankers Inc
61.840
USD
+2.79%
GRBK
Green Brick Partners Inc
65.270
USD
+5.31%
HUT
Hut 8 Corp
34.340
USD
+1.72%
GT
Goodyear Tire & Rubber Co
8.100
USD
+6.02%
TBBK
Bancorp Inc
62.030
USD
+4.29%
MCY
Mercury General Corp
91.550
USD
+3.22%
FAQ
What is Bausch Health Companies Inc (BHC) stock price today?
The current price of BHC is 6.03 USD — it has increased 0.5 % in the last trading day.
What is Bausch Health Companies Inc (BHC)'s business?
What is the price predicton of BHC Stock?
What is Bausch Health Companies Inc (BHC)'s revenue for the last quarter?
What is Bausch Health Companies Inc (BHC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bausch Health Companies Inc (BHC)'s fundamentals?
How many employees does Bausch Health Companies Inc (BHC). have?